The Ozempic catch: Why you need an exit strategy

It’s easy to understand the appeal of drugs like Ozempic, Wegovy, Mounjaro and Zepbound.

The weight comes off. Blood sugar improves. For anyone who has struggled for years with weight, diabetes or both, that can feel like a door finally opening.

But there’s one question that deserves more attention before people start:

What happens if you stop?

Not someday in theory. Six months from now, when side effects become too much, insurance stops covering it or the monthly cost becomes impossible.

Research suggests the consequences can go beyond regaining pounds. Some of the health improvements that made treatment appealing may also slip away.

Quick Answer

Stopping GLP-1 treatment may mean losing more than weight-loss benefits. In a large study of people with type 2 diabetes, stopping for one or two years was associated with a 14% or 22% higher risk of heart attack, stroke or death compared with continuous treatment. Separate weight-loss studies found substantial weight regain and reversal of metabolic improvements after withdrawal.

GLP-1 heart benefits may depend on staying on treatment

The study, published in BMJ Medicine, used health records from more than 333,000 U.S. veterans with type 2 diabetes.

Researchers compared people starting GLP-1 drugs with those starting sulfonylureas, an older class of diabetes medications. They tracked heart attacks, strokes and deaths from any cause over three years.

People who stayed on GLP-1 treatment throughout that period had an 18% lower risk of this combined outcome compared with the sulfonylurea group — roughly four fewer events per 100 people.

But stopping changed the picture.

Compared with continuous GLP-1 users, those who stopped for one year without restarting had a 14% higher risk. After two years off treatment, the risk increased to 22%.

Even a six-month interruption followed by restarting was associated with less protection than uninterrupted treatment.

These associations came from health records, not proof that stopping caused the events. The study also cannot establish those same risk increases for people without diabetes taking medication solely for weight loss. Semaglutide accounted for about two-thirds of GLP-1 treatment; tirzepatide accounted for just 0.03%.

Still, the finding raises a practical concern: continuing treatment may be central to keeping its cardiovascular benefits.

Weight regain is only the visible part

As senior author Dr. Ziyad Al-Aly put it: “Weight regain is visible; the metabolic reversal is not.”

He warned that inflammation, blood pressure and cholesterol can rebound when treatment stops.

Earlier withdrawal research helps explain that concern.

In the STEP 1 trial extension, adults without diabetes who had received semaglutide 2.4 mg for 68 weeks regained, on average, about two-thirds of their lost weight within a year after stopping. Most improvements in cardiovascular and metabolic measures shifted toward their starting levels.

Both medication and the trial’s structured lifestyle intervention ended, an important detail when interpreting the results.

A later analysis of the SURMOUNT-4 trial examined adults without diabetes who stopped tirzepatide after losing at least 10% of their weight. Within a year, about 82% regained at least one-quarter of what they had lost.

Greater regain was associated with greater reversal of improvements in waist size, blood pressure, blood sugar and other metabolic measures. Lifestyle counseling continued during that trial.

That’s why “I’ll just take it until I lose the weight” deserves a much harder look.

A smaller waist while taking medication doesn’t tell you how well the benefits will hold up after you stop.

Before starting, ask about the long-term plan

The question is not only, “Can this drug help me lose weight?”

It’s also: “Can I safely, affordably and realistically continue the treatment needed to maintain the benefit?”

For someone with type 2 diabetes, obesity or high cardiovascular risk, the potential benefits may be substantial. But a treatment decision needs to account for cost, tolerability and what happens if the medication becomes unavailable.

That discussion belongs at the beginning, while there is time to prepare.

Muscle deserves attention too, especially as we get older. Ask how your care team will address strength, nutrition and muscle preservation during weight loss. My colleague Joyce Hollman explores that concern in semaglutide melts muscle: Why that’s bad news for blood sugar.

Useful questions include:

• How long should I expect to take this medication?
• What is the plan if insurance coverage ends or side effects become difficult?
• What protein intake and resistance-training routine fit my health and abilities?
• Which symptoms require an immediate call?
• If I stop, what treatment or weight-maintenance support will replace it?
• How will we monitor blood sugar, blood pressure, cholesterol and strength — not just pounds?

If you are already taking one of these medications, discuss changes with your prescriber. If cost or side effects are pushing you toward stopping, raise the issue before a treatment gap develops.

The scale can show progress. It cannot show whether your treatment plan will remain workable six months or two years from now.

Before the first prescription, make sure the conversation includes what happens after the last dose.

Sources:

Glucagon-like peptide 1 receptor agonist discontinuation and risks of major adverse cardiovascular events in adults with type 2 diabetes: target trial emulation — BMJ Medicine, March 18, 2026.

Stopping GLP-1 drugs can quickly erase cardiovascular benefits — Washington University School of Medicine, March 18, 2026.

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension — Diabetes, Obesity and Metabolism, 2022.

Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial — JAMA Internal Medicine.

FAQs To Know Before Starting and Stopping Ozempic